Merck KGaA, Darmstadt, Germany (MKDG) has recently acquired Mirus Bio for US$600 million, with the help of global law firm White & Case LLP. This acquisition will complement MKDG’s portfolio in viral vector manufacturing and enhance its capabilities in developing novel modalities like cell and gene therapies.
White & Case LLP advised MKDG on this transaction, which is expected to close in the third quarter of 2024 pending regulatory approval and other customary conditions. The White & Case team involved in the transaction was led by partners Stefan Koch and Caitlin Powell Gimpel, and included several other partners and associates from various offices around the world.
This acquisition represents a strategic move for MKDG to further expand its presence in the development of cutting-edge therapies. For more information about this transaction, please contact your local media representative.
